Biotech Values

[DewDiligence]

…if the HCV market is over 170M patients, why are companies doing such small Ph2 trials?

Two reasons:

1. The 170M figure is an estimate for the entire world that included undiagnosed cases. The number of diagnosed patients in the markets where new HCV drugs will initially be submitted for approval is only about 5% of the above figure.

2. There are a great many permutations to test in the various phase-2 trials, which limits the practical size of enrollment in each trial due to intense competition for recruiting suitable patients.